Ibrutinib Racemate
98%
- Product Code: 100900
CAS:
936563-87-0
| Molecular Weight: | 440.5 g./mol | Molecular Formula: | C₂₅H₂₄N₆O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Ibrutinib racemate is primarily used in the development and research of treatments for various B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. It functions as a potent inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of malignant B-cells. By blocking BTK, it disrupts the signaling that promotes cancer cell growth and survival, leading to the induction of apoptosis in these cells. This makes it a valuable compound in preclinical studies and drug development aimed at creating effective therapies for B-cell-related cancers. Additionally, its racemic form is often studied to understand the pharmacokinetics, efficacy, and safety profiles of its enantiomers, which can guide the optimization of therapeutic formulations.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | Ft144,771.69 |
+
-
|
| 0.010 | 10-20 days | Ft260,647.22 |
+
-
|
Ibrutinib Racemate
Ibrutinib racemate is primarily used in the development and research of treatments for various B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. It functions as a potent inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of malignant B-cells. By blocking BTK, it disrupts the signaling that promotes cancer cell growth and survival, leading to the induction of apoptosis in these cells. This makes it a valuable compound in preclinical studies and drug development aimed at creating effective therapies for B-cell-related cancers. Additionally, its racemic form is often studied to understand the pharmacokinetics, efficacy, and safety profiles of its enantiomers, which can guide the optimization of therapeutic formulations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
Ft0.00
Ft0.00
Total :